Conditions
Cutaneous Squamous Cell Carcinoma, Endometrial Cancer, Solid Tumor
Study Overview
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) [Cohort A] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) [Cohort B].
NATIONAL TRIAL REFERENCE NUMBER
NCT06036836
When you talk with your doctor or clinical team member, please have the national trial reference number available.
Resources
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
Study Details
All patients who enroll in the trial will receive medication while on the study.
Cutaneous Squamous Cell Carcinoma (cSCC) Patients
50% will receive MK-4280A (contains favezelimab and pembrolizumab) before and after surgery.
50% will receive pembrolizumab before and after surgery.
Endometrial Cancer (EC) Patients
50% will receive MK-4280A (contains favezelimab and pembrolizumab) and lenvatinib.
50% will receive pembrolizumab and lenvatinib.
Trial Phase
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Start Date
End Date
- Actual study start date 09-29-2023
- Estimated primary completion date 03-09-2027
- Estimated study completion date 03-09-2027
Trial Locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.